FUJIFILM Irvine Scientific

What FUJIFILM Irvine Scientific does

FUJIFILM Biosciences, formerly FUJIFILM Irvine Scientific, is a wholly-owned operating subsidiary of FUJIFILM Holdings Corporation (Tokyo Stock Exchange: 4901) that develops and manufactures cell culture media and bioprocessing solutions for the biopharmaceutical industry. Founded in 1970 and headquartered in Santa Ana, California, the company serves biopharmaceutical manufacturers producing monoclonal antibodies and biologics, cell therapy developers (including CAR-T and mesenchymal stem cell programs), gene therapy manufacturers producing AAV and lentiviral vectors, and academic and research institutions. It operates globally across North America, Europe (including a manufacturing site in Tilburg, Netherlands under FUJIFILM Manufacturing Europe B.V.), and Asia-Pacific (Japan, China, India), with 251-500 employees.

The company's core technology is proprietary, chemically defined cell culture media formulations organized into three primary product families: BalanCD (CHO and HEK293 fed-batch and perfusion media for biologics and viral vector manufacturing, including BalanCD CHO Feed 4 Evo and BalanCD HEK293 Perfusion A), PRIME-XV (xeno-free, serum-free media for mesenchymal stromal and stem cell applications), and AdaptPD (platform media for CHO-MK fed-batch processes). Supporting the media portfolio are the Oceo Rover automated on-demand hydration system for powdered media and buffers, the PrimePath integrated therapy development platform combining media, reagents, services, and testing, custom media development services, custom contract manufacturing services, pyrogen and sterility testing reagents, and molecular biology and nucleic acid analysis products. Notable technical differentiators include animal-origin-free formulations designed to reduce regulatory risk in advanced therapy manufacturing, scalability for high cell density perfusion cultures, and integration of media with automation hardware to address facility footprint constraints.

FUJIFILM Biosciences operates an enterprise go-to-market model combining direct field sales for large biopharma accounts, regional distributor networks for geographic coverage, and direct online ordering via the company's own e-commerce storefront. Pricing is quote-based and not publicly disclosed, with revenue generated from one-time catalog media purchases, custom formulation and contract manufacturing services, testing reagent sales, and hardware sales of automation systems. The company sits within FUJIFILM Holdings' life sciences division, which has set a public target of 100 billion yen in life sciences revenue by FY2025, to be delivered through organic product expansion (BalanCD HEK293 Perfusion A, Oceo Rover, PrimePath) and inorganic growth, exemplified by the March 2022 acquisition of recombinant proteins manufacturer Shenandoah Biotechnology. Recent strategic activity includes collaborations with Virica Biotech on AAV production enhancers (April 2026) and with NextCell on a combined stromal cell and media platform (May 2026).

Name

FUJIFILM Irvine Scientific

Legal name

FUJIFILM Biosciences

Website

https://irvinesci.com

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

501–1,000 employees

Short description

FUJIFILM Biosciences (formerly FUJIFILM Irvine Scientific) develops and manufactures chemically defined cell culture media, reagents, and automation for biopharmaceutical manufacturers, cell and gene therapy developers, and research institutions globally. The wholly-owned FUJIFILM Holdings subsidiary is headquartered in Santa Ana, California.

Ownership category

akta.pro rank

Product category

Cell Culture Media for Bioprocessing

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Medical Equipment and Supplies Manufacturing (33911)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI)

akta.pro secondary industries

Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI), Raw Materials & Critical Reagents Supply Services (media, resins, single-use) (HLAAAKAI), Cell Culture & Bioprocess Lab Equipment (Bioreactors, Single-Use Systems, Controllers) (HLAGAIAG), Automation, Controls & Manufacturing Execution for Bioprocessing (SCADA/DCS/PLC/MES) (HLAAAJAE)

Keywords

• Cell culture media
• Bioprocessing reagents
• Cell therapy media
• Gene therapy media
• Stem cell media

Headquarters

HQ city

Santa Ana

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Cell Culture Media and Reagents: Sale of specialty cell culture media products including BalanCD, PRIME-XV, and AdaptPD product lines for biopharmaceutical manufacturing, cell therapy, and gene therapy applications
2. Custom Media Services: Custom formulation and manufacturing services for bespoke cell culture media solutions tailored to specific client bioprocessing requirements
3. Pyrogen and Sterility Testing Products: Testing reagents and solutions for quality control in biopharmaceutical manufacturing
4. Lab Automation (Oceo Rover): Automated hydration equipment and systems for media preparation at scale

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

FUJIFILM Biosciences develops and manufactures specialty cell culture media, reagents, and bioprocessing solutions for biopharmaceutical manufacturing, cell therapy, gene therapy, vaccine production, and assisted reproductive technologies. The portfolio includes chemically defined, serum-free, and animal-origin-free media under proprietary BalanCD, PRIME-XV, and AdaptPD brands, complemented by pyrogen and sterility testing reagents, the Oceo Rover automated media hydration system, and custom media formulation and contract manufacturing services.

Product overview

FUJIFILM Biosciences (formerly FUJIFILM Irvine Scientific) offers a comprehensive portfolio of cell culture media, reagents, services, and testing solutions for biopharmaceutical manufacturing. The product portfolio includes specialty cell culture media (BalanCD CHO Feed 4 Evo, AdaptPD CHO-MK Platform Media), stem cell media (PRIME-XV MSC Basal XSFM), HEK cell culture media (BalanCD HEK293 Perfusion A), and lab automation (Oceo Rover). The offerings are organized into application areas (Bioprocessing, Cell Therapy Solutions, Gene Therapy Solutions, Cell Culture) and product categories (Cell Culture and Processing, Protein and Cell Analysis, Pyrogen and Sterility Testing, Molecular Biology and Nucleic Acid Analysis, Lab Automation). The PrimePath platform provides integrated therapy development solutions, while Custom Media Services and Custom Manufacturing Services enable tailored solutions for specific customer needs.

Differentiator

Problem solved

Functional benefit

Products and services

• BalanCD CHO Feed 4 Evo Evolved fed-batch feed formulation designed to improve manufacturability and process efficiencies for CHO cell cultures, featuring increased stability and simplified hydration for scale-up of monoclonal antibody and recombinant biologic production.
• PRIME-XV MSC Basal XSFM + hPL Serum-free, chemically defined basal medium for mesenchymal stromal/stem cell (MSC) culture that provides control and consistency over MSC outcomes by enhancing cell growth and viability at every stage of research and development.
• AdaptPD CHO-MK Platform Media Platform media specifically designed for CHO-MK cell cultures in fed-batch processes, comprising AdaptPD CHO-MK Medium A and AdaptPD CHO-MK Feed 1, to accelerate biologics development for monoclonal antibody-based therapies.
• BalanCD HEK293 Perfusion A Chemically defined medium specifically optimized for high cell density (HCD), intensified processes, and perfusion cultures for AAV (adeno-associated virus) and LV (lentiviral) vector production in gene therapy manufacturing.
• Oceo Rover On-demand, automated hydration system for powdered media and buffers designed to simplify and scale production without increasing facility footprint, supporting bioprocess manufacturing flexibility.
• PrimePath Comprehensive therapy development portfolio comprising media, reagents, services, and testing capabilities designed to support biopharmaceutical production across the full path from research to commercialization.
• Custom Media Services Custom media development services that design one-of-a-kind media formulations tailored to specific customer process requirements for biopharmaceutical, cell therapy, and gene therapy applications.
• Custom Manufacturing Services Contract manufacturing services for biopharmaceutical production, supporting customers from preclinical trials through commercialization with GMP-grade media production.

Quantifiable outcome

• Improved AAV productivity through optimized viral vector production media
• +1 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Three partnerships are on record, tiered core and minor.

• NextCellcoreStrategic or Co-development Partner · 6 May 2026Launch of new commercial platform comprised of RUO (Research Use Only) stromal cells and cell culture media, combining FUJIFILM Biosciences' media expertise with NextCell's stromal cell products.
• Virica BiotechcoreStrategic or Co-development Partner · 8 April 2026Collaboration under the Canada–Japan Corporate Co-Innovation Program, supported by NRC IRAP, to optimize Virica's Viral Sensitizer (VSE™) formulation for FUJIFILM Biosciences' BalanCD HEK293 media. The partnership aims to significantly improve AAV productivity and create an off-the-shelf enhancer-media combination for gene therapy manufacturers, addressing the high cost and scalability challenges of AAV production at scale.
• DewCell BiotherapeuticsminorStrategic or Co-development Partner · 25 May 2025Partnership referenced in market context: PL BioScience partnered with South Korea's DewCell Biotherapeutics to develop fully animal-free, scalable cell culture supplements. FUJIFILM operates in same market space with similar focus on animal-origin-free solutions.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Lonza Group: Global leader in cell culture media and bioprocessing services for biopharmaceutical manufacturing. Lonza's media offerings and CDMO services directly overlap with FUJIFILM Biosciences' cell culture media and custom manufacturing businesses, serving the same biopharma and advanced therapy customers.
• Cytiva (Danaher): Major supplier of cell culture media, bioreactors, and bioprocess solutions for biopharmaceutical manufacturing. Cytiva's media portfolio and single-use technologies directly compete with FUJIFILM's BalanCD products and Oceo Rover system.
• Merck KGaA (MilliporeSigma): Life sciences division of Merck KGaA offers cell culture media, buffers, and bioprocessing reagents under the SAFC and MilliporeSigma brands. Direct overlap with FUJIFILM Biosciences' media, buffers, and custom media services.
• Sartorius AG: Provides cell culture media, bioreactors, and bioprocess solutions for biopharmaceutical manufacturers. Sartorius's media and process intensification offerings overlap with FUJIFILM's CHO media and intensified/perfusion solutions.
• Corning Life Sciences: Supplies cell culture media, sera, and bioprocess containers. Corning's media portfolio and single-use systems are direct competitors in cell culture and bioprocessing applications.
• STEMCELL Technologies: Specializes in cell culture media, reagents, and tools for stem cell research and cell therapy development. STEMCELL's media offerings compete directly with FUJIFILM's PRIME-XV MSC and other stem cell media products.

Broad incumbents

• Thermo Fisher Scientific: Diversified life sciences leader with the Gibco cell culture media business directly competing with FUJIFILM Biosciences' media products. Thermo Fisher's broader portfolio (instruments, reagents, services) gives it incumbent advantages across biopharma manufacturing workflows.
• Avantor: Distributes cell culture media, buffers, and bioprocessing materials through its own brands and partnerships. Avantor's broad portfolio and distribution reach overlap with FUJIFILM's media and buffer offerings in biopharma.
• Eppendorf: Supplies bioreactors, fermentation equipment, and bioprocess control systems. Eppendorf's bioprocess equipment portfolio is adjacent to FUJIFILM's Oceo Rover automation and bioprocessing solutions.

Emerging players

• Bio-Techne: Provides reagents and media supplements for cell therapy and regenerative medicine applications, including GMP-grade proteins. Bio-Techne's emerging focus on cell and gene therapy manufacturing overlaps with FUJIFILM's advanced therapy media portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/irvinesci
• LinkedInlinkedin.com/company/29559

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FUJIFILM Irvine Scientific